|Mr. Joseph E. Payne M.Sc.||Founder, Pres, CEO & Director||2.05M||N/A||1972|
|Dr. Padmanabh Chivukula||Founder, Chief Scientific Officer, COO & Sec.||948.31k||N/A||1979|
|Mr. Andrew H. Sassine||Chief Financial Officer||349.02k||N/A||1964|
|Mr. J.P. Headley||Associate Director of Accounting & Operations||N/A||N/A||N/A|
|Ms. Neda Safarzadeh||Director and Head of Investor Relations/PR & Marketing||N/A||N/A||N/A|
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs to treat ornithine transcarbamylase deficiency, cystic fibrosis, glycogen storage disease type 3, hepatitis B, and non-alcoholic steatohepatitis. Its RNA therapeutics platforms could be applied toward various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. It owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 154 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. The company develops RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG, and Cystic Fibrosis Foundation Therapeutics Inc. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Arcturus Therapeutics Holdings Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.